Royalty Pharma (NASDAQ:RPRX) Upgraded at StockNews.com

StockNews.com upgraded shares of Royalty Pharma (NASDAQ:RPRX) from a hold rating to a buy rating in a research note released on Monday.

Separately, Citigroup reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Royalty Pharma presently has an average rating of “Buy” and a consensus target price of $42.50.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $32.29 on Monday. Royalty Pharma has a 1-year low of $24.05 and a 1-year high of $34.20. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $18.61 billion, a price-to-earnings ratio of 22.27, a P/E/G ratio of 2.31 and a beta of 0.49. The stock’s fifty day simple moving average is $32.36 and its 200-day simple moving average is $29.88.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.07. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. The firm had revenue of $839.00 million for the quarter, compared to the consensus estimate of $724.69 million. On average, sell-side analysts predict that Royalty Pharma will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a $0.22 dividend. The ex-dividend date is Friday, May 16th. This represents a $0.88 annualized dividend and a yield of 2.73%. Royalty Pharma’s dividend payout ratio (DPR) is 47.57%.

Hedge Funds Weigh In On Royalty Pharma

Large investors have recently added to or reduced their stakes in the company. Barclays PLC grew its stake in shares of Royalty Pharma by 16.3% in the 3rd quarter. Barclays PLC now owns 308,887 shares of the biopharmaceutical company’s stock valued at $8,737,000 after purchasing an additional 43,339 shares during the period. GAMMA Investing LLC grew its position in Royalty Pharma by 31.4% during the 4th quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 590 shares during the last quarter. Pallas Capital Advisors LLC bought a new stake in Royalty Pharma during the 4th quarter worth approximately $2,355,000. Assenagon Asset Management S.A. acquired a new position in Royalty Pharma during the 4th quarter worth $486,000. Finally, Brooklyn Investment Group lifted its holdings in Royalty Pharma by 1,006.9% during the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 876 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.